Novo Nordisk plans to invest of BRL 6.4 billion ($1 billion) to expand its production facility in Montes Claros, Brazil, to increase production capacity for injectable treatments for treating  obesity, diabetes, and other chronic diseases. The expansion will increase the facility’s capacity with the addition of new aseptic production processes, a warehouse, and a new quality control laboratory. The facility will serve a variety of product formats, including glucagon-like peptide-1 (GLP-1) products. 

Construction work has begun (as reported on April 7, 2025), and operations are expected to begin in 2028. The investment is expected to create 600 permanent jobs upon completion of the facility. During the construction phase, up to 2,000 external employees will work on site 

The company has been present in Brazil since 1990 and currently has more than 2,000 employees. It is present in two locations, with an administrative office in São Paulo and the production unit in Montes Claros.   

Source: Novo Nordisk (in Portuguese)